A prospective, multicenter, open-label study to evaluate the effectiveness and the effect on cognitive function of a treatment with aripiprazole in a board range of schizophrenic patients

Trial Profile

A prospective, multicenter, open-label study to evaluate the effectiveness and the effect on cognitive function of a treatment with aripiprazole in a board range of schizophrenic patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Nov 2013

At a glance

  • Drugs Aripiprazole (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Bristol-Myers Squibb; Otsuka Pharmaceutical Development & Commercialization
  • Most Recent Events

    • 09 Feb 2010 Actual end date (Mar 2006) added as reported by ClinicalTrials.gov.
    • 30 Oct 2007 Status changed from in progress to completed.
    • 05 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top